| Oct 25 |
Monopar Therapeutics Secures License for Wilson Disease Treatment
|
| Oct 25 |
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
| Oct 24 |
Monopar stock climbs as it takes over Wilson disease drug candidate
|
| Oct 24 |
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
|
| Oct 22 |
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
|
| Oct 16 |
Monopar Therapeutics Expands Portfolio with New Patent Filing
|
| Oct 15 |
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
|
| Oct 8 |
Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial
|
| Oct 7 |
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
|
| Sep 12 |
Monopar stock rallies 60% on Phase 1 data for MNPR-101-Zr
|
